Skip to content

Press Release · Press Releases

Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale

Issued by PR Newswire

Image: PR Newswire

Phase 2 results showed EloraTZP, an investigational combination of eloralintide and tirzepatide, delivered substantial weight loss and A1C improvements in participants with obesity and type 2 diabetes Results from TRIUMPH-1, TRIUMPH-2 and TRIUMPH-4 demonstrated retatrutide, an...

This press release summary is reproduced from the issuer's public feed.

Read the full release at PR Newswire

Original publisher: PR Newswire

Spotted an error? Request a correction · Corrections Policy

Related stories

Press Release

/C O R R E C T I O N - WeaveGrid/

In the news release, North Carolina's Electric Cooperatives Launches EVConnectNC, Powered by WeaveGrid, to Maximize Charging During Lower Demand and Power Cost Periods, issued 20-Oct-2026 by WeaveGrid over PR Newswire, we are advised by the company that changes have been made. The...

PR Newswire ·